on top statins

systematic review meta-analysis network meta-analysis

Select cardiovascular prevention All type of patient       ezetimibePCSK9 Inhibitor ezetimibealirocumabevolocumab vs placebo or control       early initiation

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	cardiovascular events (3)All cause death (3)Cardiovascular death (3)Coronary event (2)Coronary death (2)stroke (fatal and non fatal) (2)myocardial infarction (fatal and non fatal) (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	cardiovascular events	All cause death
cardiovascular prevention
alirocumab
ODYSSEY OUTCOMES, 2018      NCT	alirocumab	placebo (on top statins)			Low risk of bias	conclusive
evolocumab
FOURIER, 2017      NCT	evolocumab	placebo (on top statins)			Low risk of bias	conclusive
ezetimibe
IMPROVE-IT, 2014      NCT	ezetimibe	placebo (on top statins)		early initiation	Low risk of bias	conclusive